Postpartum depression (PPD) is a major depressive episode with peripartum onset specifier (DSM-5) — onset during pregnancy or within 4 weeks postpartum (with most clinical and surveillance definitions extending the postpartum window to 12 months). PPD affects roughly 15% of new mothers in Canada (Public Health Agency of Canada Maternity Experiences Survey range; some provincial estimates run 8–19% depending on screening tool and timing). This article is a Canadian evidence-and-pathway guide to postpartum depression treatment — including a careful, honest review of where psychedelic-assisted therapy currently sits: first-line PPD treatments are CBT, IPT, and SSRIs (sertraline first-line in lactation); brexanolone (Zulresso) and zuranolone (Zurzuvae) — both PPD-specific FDA-approved neurosteroids — are NOT yet Health Canada approved; Spravato is approved for TRD in adults but the postpartum population is not specifically indicated and lactation considerations are significant; off-label ketamine in PPD has very limited published evidence; psilocybin and MDMA RCTs typically exclude pregnant, postpartum, and breastfeeding patients. Mother–infant bonding considerations, lactation pharmacokinetics, and acute suicidality requiring urgent psychiatric care are the three central safety considerations that distinguish PPD from general adult mood disorder treatment.

Key takeaways

PPD affects ~15% of new mothers in Canada. DSM-5 peripartum onset specifier covers pregnancy and the immediate postpartum period; clinical definitions typically extend through 12 months postpartum.

First-line PPD treatments are CBT, IPT, and SSRIs. Sertraline is first-line in lactation; paroxetine is also acceptable; both are safer in breastfeeding than fluoxetine. Citalopram is reasonable.

Brexanolone (Zulresso) IV is FDA-approved for severe PPD (US, 2019) but is NOT yet Health Canada approved. Zuranolone (Zurzuvae) oral neurosteroid is FDA-approved (2023) for PPD but is also NOT yet Health Canada approved.

Spravato (esketamine) is Health Canada-approved for TRD in adults — the postpartum population is not specifically indicated, and the product monograph contains lactation cautions (pumping/discarding considerations around dosing).

Off-label ketamine in PPD has very limited published evidence — emerging signal from Wisner-affiliated maternal MH research and small Kim et al. samples; lactation pharmacokinetics are real (ketamine is excreted into breastmilk) and pumping/discarding around dosing is required.

Psilocybin RCTs typically exclude pregnant, postpartum, and breastfeeding patients. Lactation pharmacokinetics for psilocybin/psilocin are unknown.

MDMA-AT RCTs typically exclude pregnant, postpartum, and breastfeeding patients.

Bipolar differential is critical — peripartum-onset bipolar I and II are common and frequently misdiagnosed initially as PPD.

Acute suicidality in PPD requires urgent psychiatric care. Crisis resources at the end of this article.

Most psychedelic-assisted therapy is NOT yet validated for PPD. Standard PPD treatments come first.

Defining postpartum depression

DSM-5 does not list "postpartum depression" as a discrete diagnosis. PPD is a major depressive episode with peripartum onset specifier — onset during pregnancy or within 4 weeks following delivery. In clinical practice and most surveillance definitions, the postpartum window is extended to 12 months postpartum.

Clinical features:

Persistent depressed mood, anhedonia, hopelessness, guilt
Sleep disturbance disproportionate to typical newborn-care sleep loss
Appetite changes
Excessive worry about infant; intrusive thoughts (often ego-dystonic)
Difficulty bonding with infant
Suicidal ideation; in severe cases thoughts of harm to infant (typically associated with postpartum psychosis rather than uncomplicated PPD — but requires urgent assessment)

Prevalence in Canada: approximately 15% of new mothers (Public Health Agency of Canada Maternity Experiences Survey range; provincial estimates run 8–19% depending on screening tool, timing, and population). Prevalence is higher with prior MDD history, prior PPD, perinatal loss, NICU admission, traumatic birth, financial stress, and inadequate social support.

Differential and comorbidity:

Postpartum anxiety — often co-occurs
Postpartum OCD — intrusive thoughts; ego-dystonic
Postpartum PTSD — particularly after traumatic delivery, NICU stay, perinatal loss
Postpartum psychosis — separate, urgent emergency requiring inpatient assessment
Peripartum-onset bipolar I/II — frequent and frequently misdiagnosed initially as unipolar PPD; mood-history screen is essential

Mother–infant bonding and lactation — the central PPD-specific considerations

PPD treatment decisions are uniquely shaped by two factors absent in general adult mood disorder treatment:

Mother–infant bonding — untreated PPD is associated with adverse outcomes for infant attachment, cognitive development, and family functioning. Treating PPD is itself protective for the infant. Decisions to delay or avoid evidence-based treatment because of theoretical lactation concerns are not always the safer choice.
Lactation pharmacokinetics — for the breastfeeding parent, every medication decision involves the relative-infant-dose (RID) and timing considerations around pumping/discarding milk.

Clinical teams (CANMAT perinatal mood disorder guidance; Wisner KL maternal MH literature; O'Hara MW PPD literature) consistently emphasize that treating PPD is the goal — and that medication selection should be made with lactation pharmacokinetics in mind, not avoided because of them.

First-line PPD treatments — the standard of care

Psychotherapy

Cognitive Behavioural Therapy (CBT) — strong evidence base for PPD; delivered individually or in group format
Interpersonal Therapy (IPT) — particularly well-studied in PPD (O'Hara et al.); addresses role transitions and interpersonal disputes characteristic of the peripartum period

Provincial public mental health programs across Canada offer perinatal-specific CBT and IPT in many regions; private psychotherapy through extended health plans is also widely available.

SSRIs in lactation

Sertraline — first-line SSRI in lactation; low relative infant dose; substantial published lactation safety data (Wisner et al.)
Paroxetine — also acceptable in lactation; low relative infant dose. Note: paroxetine carries pregnancy concerns (cardiac malformation signal in first-trimester exposure) — but in the postpartum/lactation context it is acceptable.
Citalopram / escitalopram — reasonable; somewhat higher RID than sertraline but well-tolerated
Fluoxetine — generally avoided in lactation due to long half-life and active metabolite norfluoxetine accumulating in infant; sertraline is preferred

PPD-specific neurosteroid medications — US-only at time of writing

Brexanolone (Zulresso) — IV infusion neurosteroid (allopregnanolone analogue); FDA-approved March 2019 for severe PPD. Administered as a 60-hour continuous IV infusion in REMS-certified facility. Health Canada has NOT approved brexanolone. Patients in Canada do not have access to brexanolone.
Zuranolone (Zurzuvae) — oral neurosteroid; FDA-approved August 2023 for PPD (14-day course). Health Canada has NOT approved zuranolone. Patients in Canada do not have access to zuranolone.

The absence of Health Canada approval for both brexanolone and zuranolone is a meaningful gap in Canadian PPD care. It also means that the Canadian PPD treatment landscape currently lacks a PPD-specific approved medication beyond standard SSRIs and psychotherapy.

ECT

ECT remains an evidence-based option for severe PPD — particularly with severe suicidality, psychotic features, or treatment resistance.

The PPD evidence map for psychedelic-assisted therapy

Spravato (esketamine) — TRD-approved, postpartum not specifically indicated

Health Canada approval: Spravato (esketamine) is approved for treatment-resistant depression in adults (May 2020). The postpartum population is not specifically indicated in the label.
Lactation considerations: the Spravato product monograph contains explicit lactation caution. Esketamine and ketamine pass into breastmilk. Pumping and discarding milk around dosing windows is the typical clinical approach if Spravato is used in a lactating patient.
Clinical practice: Spravato may be considered off-label for postpartum patients with TRD with careful perinatal psychiatry coordination — but is not a PPD-first-line treatment.

Off-label ketamine in PPD — very limited published evidence

Published evidence is sparse: emerging signal from Wisner-affiliated maternal MH research and small samples (Kim et al. and others); no large RCT specifically in PPD. Generalizing TRD-population ketamine RCT evidence to PPD requires caution.
Lactation pharmacokinetics: ketamine is excreted into breastmilk. Published lactation studies (limited) suggest that pumping and discarding milk for a defined window after dosing is appropriate. Specific intervals should be set by the prescribing perinatal psychiatry team.
Bonding and dissociation: ketamine sessions involve dissociation; planning for infant care during and immediately after sessions is critical.

Psilocybin — pregnant/postpartum/breastfeeding typically excluded from RCTs

Goodwin 2022 COMP001 TRD trial: pregnant and breastfeeding patients excluded
Carhart-Harris 2021 NEJM MDD trial: pregnant and breastfeeding patients excluded
MAGNUS phase 3 program: continues to exclude pregnant and breastfeeding patients
Lactation pharmacokinetics: psilocybin and its active metabolite psilocin lactation pharmacokinetics are unknown — there is no published data establishing relative infant dose or safety
Implication: psilocybin therapy is not appropriate for breastfeeding patients given the absence of safety data

MDMA-AT — pregnant/postpartum/breastfeeding typically excluded from RCTs

Mitchell 2021/2023 MAPP1/MAPP2 PTSD trials: pregnant and breastfeeding patients excluded
Mithoefer 2018: pregnant and breastfeeding patients excluded
Lactation pharmacokinetics: limited data; clinical exclusion is the standard practice

For more detail see Ketamine Therapy in Canada, Psilocybin Therapy in Canada, and Pregnancy, Postpartum, and Psychedelic-Assisted Therapy.

Decision framework — PPD-specific considerations

For postpartum patients considering psychedelic-assisted therapy:

Step	Question	Consequence
1	Is the diagnosis PPD vs peripartum-onset bipolar vs postpartum psychosis?	Comprehensive perinatal psychiatry assessment first
2	Has standard first-line treatment (CBT/IPT + sertraline) been tried at adequate dose and duration?	If not: typically pursue first
3	Is the patient breastfeeding?	Lactation pharmacokinetics drive medication selection
4	Is there acute suicidality, infant-harm ideation, or psychosis?	Urgent psychiatric care; possible inpatient
5	Is there a perinatal psychiatrist or specialty maternal mental health team involved?	Bring them in before any psychedelic-assisted therapy decision
6	What is the infant care plan during dosing sessions?	Required before any session

Canadian access pathways

Comprehensive perinatal mental health care first

Perinatal mental health services in Canada are provincially organized and uneven:

British Columbia: BC Reproductive Mental Health Program (BCRMHP) at BC Women's Hospital — flagship perinatal psychiatry service with provincial referral
Ontario: Reproductive Life Stages Program at CAMH; SickKids and Mount Sinai perinatal services; community-based perinatal teams in larger cities
Quebec: integrated perinatal services through CIUSSS structure; Pavillon Albert-Prévost perinatal psychiatry
Alberta: Alberta Health Services perinatal mental health stream (Edmonton, Calgary)
Manitoba, Saskatchewan, Atlantic provinces: smaller perinatal psychiatry capacity; tertiary referral often required
Canadian Perinatal Mental Health Collaborative (CPMHC) and the Canadian Postpartum Depression Network maintain peer-support and resource directories

Provincial maternal mental health services and family physicians remain the first stop for PPD assessment and treatment.

Off-label ketamine in PPD

Out-of-pocket dominantly: ~$400–$1,500/session
Perinatal psychiatry coordination required: not appropriate without confirmed PPD diagnosis (vs bipolar, psychosis), trial of first-line treatments, and a perinatal psychiatrist or family-medicine perinatal-mental-health-trained physician involved
Lactation planning: pumping and discarding milk around dosing per published lactation pharmacokinetics; specific intervals set by prescriber
Infant care planning: required during dosing and recovery windows

Spravato in postpartum patients

The postpartum population is not specifically indicated. Lactation considerations are significant. Spravato in a postpartum/lactating patient should be a perinatal-psychiatry-coordinated decision and is not a PPD-first-line treatment.

Psilocybin SAP and MDMA SAP in PPD

Generally not appropriate for breastfeeding patients given absence of lactation safety data. SAP applications for psilocybin or MDMA in PPD primary indication would face significant clinical resistance.
ATMA CENA will not typically support psilocybin or MDMA SAP applications for PPD primary indication.

What the evidence does NOT say

Most psychedelic-assisted therapy is NOT yet validated for PPD. Standard PPD treatments (CBT, IPT, sertraline, ECT) remain first-line and have the strongest evidence base.
Brexanolone and zuranolone — the two PPD-specific FDA-approved neurosteroids — are NOT Health Canada approved. Canadian PPD patients do not currently have access to these PPD-specific medications.
Off-label ketamine PPD evidence is preliminary. Generalizing TRD-population ketamine RCT evidence to PPD requires caution.
Psilocybin and MDMA-AT lactation safety is unestablished. Absence of evidence is not evidence of safety; clinical exclusion is the standard.
Bipolar misdiagnosis is a meaningful clinical risk in the peripartum period. Peripartum-onset bipolar I/II are frequent and frequently misdiagnosed initially as unipolar PPD.
Acute suicidality in PPD requires urgent psychiatric care. Ketamine has demonstrated rapid suicidal ideation reduction in TRD populations but does not replace acute perinatal psychiatric care.

How ATMA CENA works with PPD patients

ATMA CENA's PPD pathway emphasizes routing to standard-of-care perinatal psychiatry first:

Information call: brief clinical orientation; honest framing about where psychedelic-assisted therapy sits for PPD
Referral-out posture: ATMA CENA will route PPD patients to provincial perinatal mental health services (BCRMHP, CAMH Reproductive Life Stages, AHS perinatal MH, CIUSSS perinatal services) when not already engaged
Bipolar and postpartum psychosis screening: explicit mood and psychotic-symptoms screening at intake
Lactation pharmacokinetics consideration: every medication and dosing decision factors lactation status
Perinatal psychiatry coordination: ATMA CENA will not work with PPD patients on off-label ketamine or off-label Spravato without a perinatal psychiatrist or family-medicine perinatal-mental-health-trained physician involved
No psilocybin/MDMA for breastfeeding patients: ATMA CENA does not support psilocybin or MDMA SAP applications for PPD primary indication given lactation safety considerations

Crisis and support resources

If you are experiencing thoughts of harming yourself or your infant, call 911 or go to your nearest emergency department.

Talk Suicide Canada: 1-833-456-4566 (24/7); text 45645 (4pm–midnight ET)
9-8-8 Suicide Crisis Helpline: call or text 988 (24/7, Canada-wide)
Postpartum Support International — Canada: PSI helpline 1-800-944-4773 (English/Spanish)
Canadian Perinatal Mental Health Collaborative: provincial resource directory
Provincial maternal mental health services: BC Reproductive Mental Health Program (BCRMHP); Ontario Reproductive Life Stages Program (CAMH); Quebec CIUSSS perinatal services; Alberta Health Services perinatal mental health
Kids Help Phone (for parents of infants reaching out about distress): 1-800-668-6868

Frequently asked questions

What's PPD? Postpartum depression — a major depressive episode with peripartum onset specifier (DSM-5), onset during pregnancy or within 4 weeks postpartum (clinical and surveillance definitions typically extend to 12 months postpartum). Affects ~15% of new mothers in Canada.

What's first-line for PPD? CBT, IPT, and SSRIs. Sertraline is first-line in lactation. Paroxetine and citalopram are reasonable alternatives. Fluoxetine is generally avoided in lactation due to long half-life and active metabolite. ECT remains evidence-based for severe PPD.

Is brexanolone (Zulresso) available in Canada? No. Brexanolone is FDA-approved (US, March 2019) for severe PPD but is NOT Health Canada approved. Canadian patients do not have access.

Is zuranolone (Zurzuvae) available in Canada? No. Zuranolone is FDA-approved (US, August 2023) for PPD but is NOT Health Canada approved. Canadian patients do not have access.

Can I do Spravato if I have PPD and am breastfeeding? Spravato is Health Canada-approved for TRD in adults — the postpartum population is not specifically indicated. The product monograph contains lactation cautions. Esketamine and ketamine pass into breastmilk; pumping and discarding milk around dosing is the typical clinical approach if Spravato is used. This is a perinatal-psychiatry-coordinated decision.

Can I do off-label ketamine therapy if I have PPD and am breastfeeding? Possibly — but only with comprehensive perinatal psychiatry assessment, confirmed PPD diagnosis (vs bipolar, vs postpartum psychosis), trial of first-line treatments, lactation pumping/discarding planning, and infant care planning during dosing windows. Published PPD-specific ketamine evidence is very limited.

Can I do psilocybin therapy if I'm breastfeeding? Generally no. Psilocybin RCTs (Goodwin 2022, Carhart-Harris 2021) exclude pregnant and breastfeeding patients. Psilocybin and psilocin lactation pharmacokinetics are unknown.

Can I do MDMA-AT if I'm breastfeeding? Generally no. MDMA-AT RCTs (Mitchell 2021/2023, Mithoefer 2018) exclude pregnant and breastfeeding patients.

What if I have peripartum-onset bipolar? Comprehensive psychiatric assessment is essential. Peripartum-onset bipolar I/II are frequent and frequently misdiagnosed initially as unipolar PPD. See Bipolar Disorder and Psychedelic-Assisted Therapy — Safety Considerations.

What about postpartum psychosis? Postpartum psychosis is a psychiatric emergency — separate from PPD — typically requiring urgent inpatient assessment. Psychedelic-assisted therapy is not appropriate for postpartum psychosis.

What if I have suicidality or thoughts of harming my infant? Call 911 or go to your nearest emergency department. Call 9-8-8 (Canada-wide suicide crisis helpline) or Talk Suicide Canada at 1-833-456-4566.

Can I share my postpartum mental health history honestly with the clinical team? Yes — please do. Honest disclosure protects you and your infant. ATMA CENA's clinical team is non-judgmental and uses peripartum mental health history to make appropriate clinical decisions, not to deny care reflexively.

Sources

O'Hara MW, McCabe JE. (2013). Postpartum depression: current status and future directions. Annu Rev Clin Psychol, 9:379-407. PMID: 23394227.
Wisner KL, Sit DKY, McShea MC, et al. (2013). Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry, 70(5):490-498. PMID: 23487258.
Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. (2018). Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet, 392(10152):1058-1070. PMID: 30177236.
Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023). Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry, 180(9):668-675. PMID: 37491937.
US FDA — Zulresso (brexanolone) approval (March 2019): https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression
US FDA — Zurzuvae (zuranolone) approval (August 2023): https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression
Health Canada — Spravato Product Monograph (lactation section): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Public Health Agency of Canada — Maternity Experiences Survey and perinatal mental health surveillance: https://www.canada.ca/en/public-health/services/publications/healthy-living/maternal-mental-health-canada.html
MacQueen GM, Frey BN, Ismail Z, et al. CANMAT 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder — Section 6: Special Populations (perinatal). Can J Psychiatry, 61(9):588-603. PMID: 27486149.
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Sockol LE, Epperson CN, Barber JP. (2011). A meta-analysis of treatments for perinatal depression. Clin Psychol Rev, 31(5):839-49. PMID: 21545782.
Berle JØ, Spigset O. (2011). Antidepressant Use During Breastfeeding. Curr Womens Health Rev, 7(1):28-34. PMID: 22299006.

Last updated: 2026-05-06

Postpartum Depression and Psychedelic-Assisted Therapy in Canada

Access and legality vary by jurisdiction